

BIOCON GROUP

FACT SHEET

June - 2018

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		
	(Rs Cr)	
	June 30, 2018	March 31, 2018
ASSETS		
Non-current assets		
(a) Property, plant and equipment	3,843	3,630
(b) Capital work-in-progress	873	779
(c) Investment property	-	-
(d) Goodwill	14	26
(e) Other intangible assets	41	43
(f) Intangible assets under development	588	524
(g) Investments in associates and a joint venture	64	64
(h) Financial assets	-	-
Investments	85	-
Derivative assets	81	111
Other financial assets	25	25
(i) Income-tax asset, net	148	127
(j) Deferred tax asset, net	331	193
(k) Other non-current assets	320	319
	6,413	5,841
Current assets		
(a) Inventories	814	723
(b) Financial assets		
Investments	545	611
Trade receivables	1,093	1,064
Cash and cash equivalents	442	501
Other bank balances	1,097	822
Derivative assets	61	99
Other financial assets	241	192
(c) Other current assets	153	137
	4,446	4,149
TOTAL	10,859	9,990
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	300	300
(b) Other equity	5,056	4,881
Equity attributable to owners of the Company	5,356	5,181
Non-controlling interests	496	468
	5,852	5,649
Non-current liabilities		
(a) Financial liabilities		
Borrowings	1,816	1,790
Derivative liability	94	18
Other financial liabilities	-	-
(b) Provisions	52	49
(c) Other non-current liabilities	539	342
	2,501	2,199
Current liabilities		
(a) Financial liabilities		
Borrowings	253	130
Trade payables	1,051	1,006
Derivative liability	31	6
Other financial liabilities	667	556
(b) Provisions	53	47
(c) Income tax liability, net	200	89
(d) Other current liabilities	251	308
	2,506	2,142
TOTAL	10,859	9,990

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q1 FY 19	Q1 FY 18	Variance
<u>INCOME</u>			
Small molecules	400	363	10%
Biologics	250	184	36%
Branded formulations	147	130	13%
Research services	406	291	39%
Inter-segment	(79)	(34)	129%
Revenue from operations #	1,124	934	20%
Other income	69	54	27%
TOTAL REVENUE	1,193	988	21%
<u>EXPENDITURE</u>			
Material & Power costs	491	410	20%
Staff costs	237	193	23%
Research & Development expenses*	44	58	-24%
Other expenses	114	81	42%
Manufacturing, staff & other expenses	886	742	19%
EBITDA	307	246	25%
Interest & Finance charges	18	16	9%
Depreciation & Amortisation	99	99	0%
Share of profit in JV / Associate, net	(1)	(4)	-88%
PBT BEFORE EXCEPTIONAL ITEM	191	135	41%
Exceptional item, Net	-	-	-
PBT	191	135	41%
Taxes	52	38	39%
Taxes on exceptional item	-	-	-
NET PROFIT BEFORE MINORITY INTEREST	139	97	42%
Minority interest	19	16	13%
NET PROFIT FOR THE PERIOD	120	81	47%
EPS Rs.	2.0	1.4	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	5	8	
* Gross Research & Development expenses	88	96	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q1 FY 19	Q4 FY 18	Variance
INCOME			
Small molecules	400	426	-6%
Biologics	250	241	4%
Branded formulations	147	149	-1%
Research services	406	409	-1%
Inter-segment	(79)	(55)	44%
Revenue from operations #	1,124	1,170	-4%
Other income	69	67	2%
TOTAL REVENUE	1,193	1,237	-4%
EXPENDITURE			
Material & Power costs	491	523	-6%
Staff costs	237	234	1%
Research & Development expenses*	44	51	-13%
Other expenses	114	129	-12%
Manufacturing, staff & other expenses	886	937	-5%
EBITDA	307	300	2%
Interest & Finance charges	18	17	4%
Depreciation & Amortisation	99	95	4%
Share of profit in JV / Associate, net	(1)	(5)	-90%
PBT BEFORE EXCEPTIONAL ITEM	191	193	-1%
Exceptional item, Net	-	-	-
PBT	191	193	-1%
Taxes	52	41	28%
NET PROFIT BEFORE MINORITY INTEREST	139	152	-9%
Minority interest	19	22	-17%
NET PROFIT FOR THE PERIOD	120	130	-8%
EPS Rs.	2.0	2.2	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	5	2	
* Gross Research & Development expenses	88	98	